- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05718375
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
February 6, 2023 updated by: Curacle Co., Ltd.
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria
To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
240
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hyunjeong Kim
- Phone Number: +82-2-3487-0077
- Email: hjkim02@curacle.com
Study Locations
-
-
-
Daegu, Korea, Republic of
- Recruiting
- Yeongnam University Medical Center
-
Contact:
- KyuChang Won
- Phone Number: +82-53-620-3846
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male/female patients aged 30 years or above
- Patients diagnosed as type 2 diabetes prior to screening
- Patients receiving ACE inhibitors (angiotensin-converting-enzyme inhibitor) or ARB (angiotensin II receptor blockers) for at least 8 weeks prior to screening
- Patients who experienced albuminuria (albumin to creatinine ratio) 200~1,000 mg/g Cr) at least twice prior to 24weeks including screening results
- Patients with blood pressure ≤ 140/90mmHg at screening
- Patients with 25 ≤ GFR (glomerular filtration rate) ≤ 75ml/min/1.73m2 at screening
- Patients with 6.5% < HbA1c ≤ 9% at screening
Exclusion Criteria:
- Patients with past medical history of acute renal failure within 12weeks prior to screening; or Increase in SCr ≥ 0.3 mg/dL within 48 hours; or an increase in SCr ≥ 1.5-fold from baseline (the lowest value) within 12 weeks; or urine output <0.5mg/kg/hour for 6 hours
- NYHA class III~IV
- Patients with medical history related liver disease and hepatic function as follows: ALT (alanine aminotransferase) or AST (aspartate aminotransferase) >3 X institutional upper limit of normal (ULN), or Total bilirubin >3 X institutional upper limit of normal (ULN)
- Patients with malabsorption due to organic gastrointestinal disorder or chronic gastroenterological disorders at screening (short-bowel syndrome, active Crohn's disease, and ulcerative colitis, etc.)
- Patients with acute disease (including infectious diseases) at screening and who are thought to be unable to participate in the clinical study)
- Within 12 weeks of the informed consent, patients who had the diagnosis and procedures of the following cardiovascular diseases: cardiac failure (NYHA class III and IV), unstable angina pectoris, myocardial infarction, transient ischemic attack, cerebro-vascular accident, history of peripheral vascular disease or coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty
- Patients with history of alcohol or drug abuse
- Patients with any allergic reaction to the investigational product or its components
- Patients who are planning to receive dialysis or renal transplantation within 36 weeks (9 months) in the future
- Patients who are expected to have lower compliance with protein-limited diets and the use of the study drug
- Women who are pregnant or breastfeeding a baby
- Women who are able to become pregnant and do not agree to use acceptable contraception as defined by the protocol; however, women of childbearing potential who have not gone sterility procedures can participate in the study only for negative pregnancy test, and should agree to maintain effective contraception (implants of intrauterine device or intrauterine system, double barrier contraception (condom, diaphragm, sponge or cervical cap with spermicide), oral contraceptives, sterilization, and total abstinence) throughout the study
- Patients who participated in other clinical study within 12 weeks of the participation in this study
- Patients who are not eligible for this study participation in the judgment of the principal investigator or sub-investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CU01-1001 (low dose)
1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)
|
Placebo
CU01-1001
|
EXPERIMENTAL: CU01-1001 (high dose)
1 Tab/3 times/day (CU01-1001 120 mg, Breakfast, Lunch, and Dinner)
|
CU01-1001
|
PLACEBO_COMPARATOR: Placebo
1 Tab/3 times/day (Placebo, Breakfast, Lunch, and Dinner)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline
Time Frame: Day 0, 24 weeks
|
Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baseline
|
Day 0, 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: KyuChang Won, Yeongnam University Medical Center
- Principal Investigator: HyeJin Yoo, Koera University Guro Hospital
- Principal Investigator: Jun Hwa Hong, Eulji University Hospital
- Principal Investigator: Young Min Cho, Seoul National University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 25, 2023
Primary Completion (ANTICIPATED)
September 30, 2024
Study Completion (ANTICIPATED)
September 30, 2024
Study Registration Dates
First Submitted
January 27, 2023
First Submitted That Met QC Criteria
February 6, 2023
First Posted (ACTUAL)
February 8, 2023
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CU01-1001-DN-P2b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathies
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
-
University of MilanActive, not recruitingDiabetic Nephropathy Type 2Italy
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States